There is a pressing need for robust longitudinal cohort studies in the modern treatment era of multiple sclerosis.
Objective:
Build a multiple sclerosis (MS) cohort repository to capture the variability of disability accumulation, as well as provide the depth of characterization (clinical, radiologic, genetic, biospecimens) required to adequately model and ultimately predict a patient’s course.
Methods:
Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) is an international multi-center, prospectively enrolled cohort with over a decade of comprehensive follow-up on more than 1000 patients from two large North American academic MS Centers (Brigham and Women’s Hospital (Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women’s Hospital (CLIMB; BWH)) and University of California, San Francisco (Expression/genomics, Proteomics, Imaging, and Clinical (EPIC))). It is bringing online more than 2500 patients from additional international MS Centers (Basel (Universitätsspital Basel (UHB)), VU University Medical Center MS Center Amsterdam (MSCA), Multiple Sclerosis Center of Catalonia-Vall d’Hebron Hospital (Barcelona clinically isolated syndrome (CIS) cohort), and American University of Beirut Medical Center (AUBMC-Multiple Sclerosis Interdisciplinary Research (AMIR)).
Results and conclusion:
We provide evidence for harmonization of two of the initial cohorts in terms of the characterization of demographics, disease, and treatment-related variables; demonstrate several proof-of-principle analyses examining genetic and radiologic predictors of disease progression; and discuss the steps involved in expanding SUMMIT into a repository accessible to the broader scientific community.
ConfavreuxCVukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126: 770–782.
2.
ConfavreuxCVukusicSMoreauTet al. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–1438.
3.
DebouverieMPittion-VouyovitchSLouisSet al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol2008; 15: 916–921.
4.
PittockSJMayrWTMcClellandRLet al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology2004; 62: 601–606.
5.
TremlettHPatyDDevonshireV. The natural history of primary progressive MS in British Columbia, Canada. Neurology2005; 65: 1919–1923.
6.
TremlettHPatyDDevonshireV. Disability progression in multiple sclerosis is slower than previously reported. Neurology2006; 66: 172–177.
7.
TremlettHZhaoYRieckmannPet al. New perspectives in the natural history of multiple sclerosis. Neurology2010; 74: 2004–2015.
8.
WeinshenkerBGBassBRiceGPet al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain1989; 112(Pt 1): 133–146.
9.
WeinshenkerBGBassBRiceGPet al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain1989; 112(Pt 6): 1419–1428.
10.
BrexPACiccarelliOO’RiordanJIet al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med2002; 346: 158–164.
11.
CreeBAHartungHP. Steering through complexity: Management approaches in multiple sclerosis. Curr Opin Neurol2016; 29: 263–271.
12.
ProsperiniLGalloVPetsasNet al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol2009; 16: 1202–1209.
13.
RomeoMMartinelli-BoneschiFRodegherMet al. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients. Eur J Neurol2013; 20: 1060–1067.
14.
TrojanoMPellegriniFPaolicelliDet al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol2009; 66: 513–520.
15.
ButzkuevenHChapmanJCristianoEet al. MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler2006; 12: 769–774.
16.
JokubaitisVGSpelmanTKalincikTet al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol2016; 80: 89–100.
17.
BaranziniSEGalweyNWWangJet al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet2009; 18: 2078–2090.
18.
GauthierSAGlanzBIMandelMet al. A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study. Autoimmun Rev2006; 5: 532–536.
19.
PolmanCHRudickRA. The multiple sclerosis functional composite: A clinically meaningful measure of disability. Neurology2010; 74 (Suppl. 3): S8–S15.
20.
McDonaldWICompstonAEdanGet al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121–127.
21.
CreeBAGourraudPAOksenbergJRet al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol2016; 80: 499–510.
22.
TintoreMRoviraARioJet al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015; 138: 1863–1874.
23.
GoodinDSTraboulseeAKnappertzVet al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry2012; 83: 282–287.
24.
BoveRMHealyBAugustineAet al. Effect of gender on late-onset multiple sclerosis. Mult Scler2012; 18: 1472–1479.
25.
TrojanoMPellegriniFFuianiAet al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol2007; 61: 300–306.
26.
BevanCJCreeBA. Disease activity free status: A new end point for a new era in multiple sclerosis clinical research?JAMA Neurol2014; 71: 269–270.
27.
RotsteinDLHealyBCMalikMTet al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol2015; 72: 152–158.
28.
KapposLDe StefanoNFreedmanMSet al. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler2016; 22: 1297–1305.
29.
KeshavanAPaulFBeyerMKet al. Power estimation for non-standardized multisite studies. NeuroImage2016; 134: 281–294.
30.
PatsopoulosNABarcellosLFHintzenRQet al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet2013; 9: e1003926.
SawcerSHellenthalGPirinenMet al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476: 214–219.
33.
BeechamAHPatsopoulosNAXifaraDKet al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet2013; 45: 1353–1360.
34.
MastermanTLigersAOlssonTet al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol2000; 48: 211–219.
35.
CreeBAReichDEKhanOet al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol2009; 66: 226–233.
36.
De JagerPLChibnikLBCuiJet al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol2009; 8: 1111–1119.
37.
HensiekAESawcerSJFeakesRet al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry2002; 72: 184–187.
38.
XiaZWhiteCCOwenEKet al. GEMS project: A platform to investigate multiple sclerosis risk. Ann Neurol2016; 79: 178–189.
39.
MuellerSGWeinerMWThalLJet al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am2005; 15: 869–877, xi–xii.
40.
DawberTRMeadorsGFMooreFEJr.Epidemiological approaches to heart disease: The Framingham study. Am J Public Health Nations Health1951; 41: 279–281.
41.
LongMTFoxCS. The Framingham heart study–67 years of discovery in metabolic disease. Nat Rev Endocrinol2016; 12: 177–183.
42.
Schulze-TopphoffUCasazzaSVarrin-DoyerMet al. Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med2013; 210: 1301–1309.
43.
CorvolJCPelletierDHenryRGet al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A2008; 105: 11839–11844.
44.
OttoboniLKeenanBTTamayoPet al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med2012; 4: 153ra31.
45.
BakshiRYesteAPatelBet al. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2016; 3: e200.
46.
GandhiRHealyBGholipourTet al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol2013; 73: 729–740.
47.
HoutchensMKBenedictRHKillianyRet al. Thalamic atrophy and cognition in multiple sclerosis. Neurology2007; 69: 1213–1223.
48.
RoccaMAMesarosSPaganiEet al. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology2010; 257: 463–469.
49.
ChuRTauhidSGlanzBIet al. Whole brain volume measured from 1.5T versus 3T MRI in healthy subjects and patients with multiple sclerosis. J Neuroimaging2016; 26: 62–67.
50.
RudickRALeeJCNakamuraKet al. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci2009; 282: 106–111.
51.
FisherELeeJCNakamuraKet al. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol2008; 64: 255–265.
52.
HorsfieldMASalaSNeemaMet al. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis. NeuroImage2010; 50: 446–455.
53.
CohenABNeemaMAroraAet al. The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging2012; 22: 122–128.
54.
PapinuttoNSchlaegerRPanaraVet al. Age, gender and normalization covariates for spinal cord gray matter and total cross-sectional areas at cervical and thoracic levels: A 2D phase sensitive inversion recovery imaging study. PloS ONE2015; 10: e0118576.
55.
PapinuttoNSchlaegerRPanaraVet al. 2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times. JMRI2015; 42: 698–708.
56.
SchlaegerRPapinuttoNZhuAHet al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol2015; 72: 897–904.
57.
SchlaegerRPapinuttoNPanaraVet al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol2014; 76: 568–580.
58.
GourraudPAHenryRGCreeBAet al. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol2014; 76: 633–642.
59.
FinkelsteinDM. A proportional hazards model for interval-censored failure time data. Biometrics1986; 42: 845–854.
60.
HealyBCLiguoriMTranDet al. HLA B*44: Protective effects in MS susceptibility and MRI outcome measures. Neurology2010; 75: 634–640.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
